SCPH

scPharmaceuticals Inc. (SCPH) | Rumor.io

scPharmaceuticals

SCPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SCPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 25

$SCPH has been acquired by $MNKD for up to $6.35 per share in cash.
The acquisition is expected to accelerate revenue growth and add the FDA-approved CHF/CKD therapy FUROSCIX to $MNKD's portfolio.
$MNKD is expected to launch a tender offer to acquire all outstanding $SCPH shares and submit a sNDA for the autoinjector in Q3 2025.

Generated by AI

Sentiment

Of the messages about SCPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.27% -1.2
Bearish	—	—	—	9.73% +1.2

Bullish· Aug 25

$SCPH's acquisition by $MNKD expands its footprint into cardiorenal, targeting significant synergy in patients with fluid overload and diabetes.
The deal accelerates $SCPH's revenue growth, with Mannkind's acquisition expected to put them at $370M.
$SCPH's shareholders can now buy more shares with the money received from the acquisition, potentially leading to a 10x return over the next 2 years.

Bearish· Mar 7

The company's stock price may drop further if it fails to beat top and bottom line estimates.
The FDA news was already priced in, and the company's officers did not expect the stock to perform as well as it did.
The stock's price reflects a lack of confidence in the company's ability to become profitable within its projected timeline.

Generated by AI

Topics

Of the messages about SCPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	3.32%
Macro	—	—	—	0%
Earnings	—	—	—	4.74%
Controversies	—	—	—	0.95%
Announcements	—	—	—	85.78%
Analysts	—	—	—	5.21%

Analysts· Jun 14

BMO Capital maintains an "Outperform" rating for scPharmaceuticals with a $14 target price, but lowers estimates due to a potential 1- to 2-year delay.
Jefferies and Leerink both lower their price targets for scPharmaceuticals to $12, with Jefferies maintaining a "Buy" rating.
BMO Capital, Jefferies, and Leerink all have an "Outperform" or "Buy" rating for scPharmaceuticals, with target prices ranging from $12 to $14.

Announcements· Aug 12

scPharmaceuticals announced FDA approval of its Supplemental New Drug Application to expand the FUROSCIX indication for heart failure patients, including those with NYHA Class IV chronic heart failure.
The company secured non-dilutive financings totaling up to $125 million with Perceptive Advisors, which will be used to repay existing debt and fund activities related to the commercialization of FUROSCIX.
scPharmaceuticals priced an underwritten public offering of 12 million shares of its common stock at $4.00 per share, with the proceeds to be used for general corporate purposes.

Generated by AI

Community

Of the messages about SCPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	56.54%
Newcomers	—	—	0%	43.46%

Regulars· Apr 13

The regulars are focused on the recent volume spike in $SCPH, with some speculating that a news leak may be responsible.
The asset is expected to transform heart congestion management, with a potential $500M peak sales estimate and 100% Medicare reimbursement, leading to a $2B market capitalization.
The Aroon Indicator has entered an uptrend for $SCPH, and trailing stops with EMAs may help protect profits as the stock continues to trend upward.

Newcomers· Oct 12

Newcomers are noting that SCPH has been performing well, with one user stating it's a "quiet play" and another saying it's been a "banger".
Some newcomers are discussing SCPH's recent price movements, with one user mentioning a 7% increase and another noting a failed AM pop.
Users are also highlighting SCPH's potential for further growth, with one user stating they have a "positive outlook on the future" and another mentioning the need to "establish your own price targets".

Generated by AI

Also Discussed

Investors talking about SCPH also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Seres Therapeutics Inc.MCRB	0%0
3	YMAB - Y-mAbs Therapeutics, Inc.	——
4	ETNB - 89bio, Inc.	——
5	UroGen Pharma Ltd.URGN	0%new
6	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
7	Milestone Pharmaceuticals Inc.MIST	0%+0
8	Arcutis Biotherapeutics, Inc.ARQT	0%+0
9	Rhythm Pharmaceuticals, Inc.RYTM	0%0
10	Cassava Sciences Inc.SAVA	0%new